Debt pressures cast cloud over Fosun Pharma results
复星医药收入微增 惟债务压力惹关注

The drugmaker eked out a 0.16% rise in first-half revenue, but underlying net profit slipped 26% as waning sales of Covid treatments and foreign exchange losses squeezed earnings
受抗疫产品收入锐减、美元升值导致汇兑损失等因素影响，这家综合制药集团上半年收入仅增长0.16%，扣除非经常性损益的净利润更下滑26.28%。